QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NASDAQ:ALLO

Allogene Therapeutics (ALLO) Stock Price, News & Analysis

$4.36
-0.08 (-1.80%)
(As of 02/22/2024 ET)
Today's Range
$4.23
$4.52
50-Day Range
$2.71
$4.96
52-Week Range
$2.23
$7.14
Volume
2.96 million shs
Average Volume
2.96 million shs
Market Capitalization
$733.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.29

Allogene Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
250.7% Upside
$15.29 Price Target
Short Interest
Healthy
22.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.11mentions of Allogene Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$50,328 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.03) to ($1.88) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.43 out of 5 stars

Medical Sector

300th out of 934 stocks

Biological Products, Except Diagnostic Industry

45th out of 160 stocks


ALLO stock logo

About Allogene Therapeutics Stock (NASDAQ:ALLO)

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

ALLO Stock Price History

ALLO Stock News Headlines

Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE!
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets…FOR FREE!
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update
Allogene Therapeutics Inc (ALLO)
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE!
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets…FOR FREE!
Allogene Therapeutics To Lay Off 22% Of Its Workforce; Stock Down
See More Headlines
Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/02/2023
Today
2/22/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALLO
Fax
N/A
Employees
359
Year Founded
2018

Price Target and Rating

Average Stock Price Target
$15.29
High Stock Price Target
$31.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+250.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-332,630,000.00
Net Margins
-178,954.28%
Pretax Margin
-178,954.27%

Debt

Sales & Book Value

Annual Sales
$240,000.00
Book Value
$4.62 per share

Miscellaneous

Free Float
122,169,000
Market Cap
$733.70 million
Optionable
Optionable
Beta
0.73

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Arie S. Belldegrun F.A.C.S. (Age 75)
    M.D., Co-Founder & Executive Chairman
    Comp: $714.25k
  • Dr. David D. Chang M.D. (Age 64)
    Ph.D., Co-Founder, President, CEO & Director
    Comp: $1.1M
  • Mr. Joshua A. Kazam (Age 47)
    Co-Founder & Director
    Comp: $711k
  • Mr. Geoffrey M. Parker (Age 60)
    Executive VP & CFO
  • Mr. Timothy L. Moore Ph.D. (Age 63)
    Executive VP & Chief Technical Officer
  • Mr. Earl M. Douglas Esq. (Age 61)
    General Counsel & Compliance Officer
  • Ms. Susan R. Lundeen (Age 58)
    Chief People Officer
  • Ms. Christine Cassiano
    Executive VP, Chief Corporate Affairs & Brand Strategy Officer
  • Dr. Zachary J. Roberts M.D. (Age 46)
    Ph.D., Executive VP of Research & Development and Chief Medical Officer
  • Yinlin Chen
    Senior Vice President of Finance














ALLO Stock Analysis - Frequently Asked Questions

Should I buy or sell Allogene Therapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALLO shares.
View ALLO analyst ratings
or view top-rated stocks.

What is Allogene Therapeutics' stock price target for 2024?

11 analysts have issued 12-month target prices for Allogene Therapeutics' stock. Their ALLO share price targets range from $6.00 to $31.00. On average, they predict the company's stock price to reach $15.29 in the next year. This suggests a possible upside of 250.7% from the stock's current price.
View analysts price targets for ALLO
or view top-rated stocks among Wall Street analysts.

How have ALLO shares performed in 2024?

Allogene Therapeutics' stock was trading at $3.21 at the beginning of 2024. Since then, ALLO stock has increased by 35.8% and is now trading at $4.36.
View the best growth stocks for 2024 here
.

Are investors shorting Allogene Therapeutics?

Allogene Therapeutics saw a drop in short interest in January. As of January 31st, there was short interest totaling 23,090,000 shares, a drop of 23.6% from the January 15th total of 30,210,000 shares. Based on an average trading volume of 3,120,000 shares, the short-interest ratio is currently 7.4 days. Currently, 22.2% of the company's stock are short sold.
View Allogene Therapeutics' Short Interest
.

When is Allogene Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our ALLO earnings forecast
.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.06. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.01 million. Allogene Therapeutics had a negative net margin of 178,954.28% and a negative trailing twelve-month return on equity of 54.03%. Allogene Therapeutics's revenue for the quarter was down 48.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.52) EPS.

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.37%), Primecap Management Co. CA (3.14%), Goldman Sachs Group Inc. (1.98%), Price T Rowe Associates Inc. MD (1.41%), Price T Rowe Associates Inc. MD (1.41%) and Dimensional Fund Advisors LP (0.91%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Deborah M Messemer, Eric Thomas Schmidt, Owen N Witte, Owen N Witte, Rafael Amado, Stephen Mayo and Veer Bhavnagri.
View institutional ownership trends
.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALLO) was last updated on 2/22/2024 by MarketBeat.com Staff